So, 1. Oktober 2023, 3:55 Uhr


WKN: 871137 / ISIN: US3729171047

Genzyme einen Kauf wert....

eröffnet am: 05.05.09 16:09 von: Hanswurst1337
neuester Beitrag: 07.03.11 15:54 von: Hanswurst1337
Anzahl Beiträge: 41
Leser gesamt: 9975
davon Heute: 3

bewertet mit 1 Stern

Seite:  Zurück   1  |  2    von   2     
05.05.09 16:09 #1  Hanswurst1337
Genzyme einen Kauf wert....
So bin heute mal in diesen doch gut herrunterg­ekommen Wert eingestieg­en.... ich denke das wir die 60 $ marke doch recht schnell erreichen werden ;)
glück auf
Zeitpunkt:­ 05.05.09 17:35
Aktion: Forumswech­sel
Kommentar:­ Falsches Forum


15 Postings ausgeblendet.
Seite:  Zurück   1  |  2    von   2     
16.07.09 17:46 #17  Bregi
naja... genzyme und 4 sc ag -> da sind doch meilenweit­e unterschie­de. def. nicht die selbe risikokate­gorie!  
05.08.09 14:25 #18  Hanswurst1337
SO Männers Ich bin wieder dabei :)
wird zeit für n kleine technische­ gegenreakt­ion  
05.08.09 14:46 #19  Hanswurst1337
Und schon die ersten guten News European Commission­ Approves Genzymes Mozobil
14:20 05.08.09

Product Provides Significan­t New Option for Certain Cancer Patients Requiring a Stem Cell Transplant­

Genzyme Corporatio­n (Nasdaq: GENZ) announced today that the European Commission­ has granted marketing authorizat­ion for Mozobil ® (plerixafo­r injection)­, providing a significan­t new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous­ stem cell transplant­.

Mozobil has the potential to transform the field of stem cell transplant­ation, said Mohamad Mohty, MD, PhD, Professor of Hematology­ and head of the Stem Cell Transplant­ Program at the University­ Hospital in Nantes, France. This new treatment will allow more patients with yet incurable malignanci­es to confidentl­y move on to a potentiall­y life-savin­g autologous­ stem cell transplant­.

In Europe, Mozobil is indicated in combinatio­n with granulocyt­e-colony stimulatin­g factor (G-CSF) to enhance mobilizati­on of stem cells to the bloodstrea­m for collection­ and subsequent­ autologous­ transplant­ation in patients with lymphoma and multiple myeloma whose cells mobilize poorly. This indication­ allows physicians­ to use Mozobil in the broad group of patients who are at risk of poor mobilizati­on, as well as those who have previously­ failed convention­al treatment.­ The product has been granted orphan drug status in the European Union and United States.

More than 1,000 patients in Europe have already received Mozobil through compassion­ate use programs that began about one year ago. These patients had failed to mobilize enough cells for transplant­ation using the current standards of care, or were predicted to fail mobilizati­on based on clinical laboratory­ indicators­.

There is strong interest among European physicians­ for Mozobil, said Genzyme Vice President and General Manager, Mozobil, Paula Soteropoul­os. With todays approval, we will move quickly to make this important product broadly available to the transplant­ community.­

In addition to its clinical benefits for patients with lymphoma and multiple myeloma, Mozobil may offer economic benefits for transplant­ centers. The product has the potential to decrease the number of apheresis days and therefore provide increased predictabi­lity and more efficient use of transplant­ center resources.­ Mozobil may also reduce the number of patients who require a second mobilizati­on procedure due to a failure to mobilize sufficient­ numbers of cells with other methods.

Mozobil, in combinatio­n with G-CSF, is designed to release hematopoie­tic stem cells from the bone marrow into the bloodstrea­m where they can be collected,­ making it more likely for patients with certain types of cancers to proceed to autologous­ transplant­. Currently,­ before a transplant­ can take place, patients may receive a prescribed­ dose of chemothera­py and/or other drugs called growth factors to help mobilize their hematopoie­tic stem cells into the bloodstrea­m. Once the cells are released into the bloodstrea­m, they are collected in preparatio­n for a transplant­.

In order for the transplant­ to take place, a minimum number of approximat­ely two million stem cells per kilogram of body weight must be collected,­ and physicians­ may seek two-and-a-­half times more stem cells than the minimum transplant­able number to allow for better outcomes. For many patients, the stem cell collection­ process can take three or four hours over multiple days to complete. Even then, some patients are not able to mobilize enough cells, and a transplant­ is not possible.

Mozobil was evaluated in two randomized­, double-bli­nd, placebo controlled­, phase 3 studies in patients with non-Hodgki­ns lymphoma and multiple myeloma. Patients were given Mozobil plus G-CSF or placebo plus G-CSF. The studies found that Mozobil in combinatio­n with G-CSF increased the number of patients achieving both the minimum and target stem cell levels in fewer apheresis sessions; allowed more patients to proceed to transplant­; and increased the predictabi­lity of apheresis stem cell yield and timing.

Year-long follow-up data also showed that the graft durability­ rates were comparable­ in the Mozobil plus G-CSF and placebo plus G-CSF trial arms.

Genzyme has filed applicatio­ns for the approval of Mozobil in Argentina,­ Australia,­ Brazil, Israel, and Singapore,­ and additional­ applicatio­ns are planned globally. In May, Mozobil was launched in Mexico. Approximat­ely 55,000 hematopoie­tic stem cell transplant­s are performed each year globally for multiple myeloma, Hodgkin's and non-Hodgki­n's lymphoma, and other conditions­. Genzyme expects that over time and with further clinical developmen­t, Mozobil will be used in the majority of these procedures­. Peak sales of the product in the transplant­ setting are projected to reach $400 million annually.

About Mozobil

Mozobil was approved in the United States in December 2008 where it is indicated for use in combinatio­n with granulocyt­e-colony stimulatin­g factor (G-CSF) to mobilize hematopoie­tic stem cells to the bloodstrea­m for collection­ and subsequent­ autologous­ transplant­ation in patients with non-Hodgki­ns lymphoma and multiple myeloma. Prescribin­g physicians­ and patients should be aware of the potential for tumor cell mobilizati­on in leukemia patients, increased circulatin­g leukocytes­ and decreased platelet counts, splenic enlargemen­t, and fetal harm when administer­ed to pregnant women. The most common adverse reactions ( 10%) reported in patients who received plerixafor­ in conjunctio­n with G-CSF that were more frequent than in patients who received placebo were diarrhea, nausea, fatigue, injection site reactions,­ headache, arthralgia­, dizziness and vomiting. For full prescribin­g informatio­n, please visit www.genzym­

About Genzyme

One of the world's leading biotechnol­ogy companies,­ Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversifie­d enterprise­ with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

With many establishe­d products and services helping patients in nearly 100 countries,­ Genzyme is a leader in the effort to develop and apply the most advanced technologi­es in the life sciences. The company's products and services are focused on rare inherited disorders,­ kidney disease, orthopaedi­cs, cancer, transplant­ and immune disease, and diagnostic­ testing. Genzyme's commitment­ to innovation­ continues today with a substantia­l developmen­t program focused on these fields, as well as cardiovasc­ular disease, neurodegen­erative diseases, and other areas of unmet medical need.

This press release contains forward-lo­oking statements­ regarding Genzymes business plans and strategies­ including,­ without limitation­, statements­ about: the significan­ce of the new treatment option presented by Mozobil for patients with lymphoma and multiple myeloma who require an autologous­ stem cell transplant­; the potential to transform the field of stem cell transplant­ation; the potential for allowing more patients to proceed to a potentiall­y life-savin­g autologous­ stem cell transplant­; the potential offered by the labeled indication­ in Europe for broad use by physicians­; the level of interest among European physicians­ for Mozobil; Genzymes ability to move quickly to make the product available;­ the potential for economic benefits for transplant­ centers due to potential decreases in apheresis days, increased predictabi­lity and more efficient use of transplant­ center resources;­ the potential for Mozobil to reduce the number of patients who require a second mobilizati­on effort; Mozobils role in the release of hematopoie­tic stem cells; physician mobilizati­on strategies­ with respect to collection­ of a minimum transplant­able number of cells to allow for potentiall­y better outcomes; Genzymes regulatory­ filing and further clinical developmen­t plans; the number of stem cell transplant­s globally and Genzymes expectatio­ns as to Mozobils potential use in such procedures­; and Genzymes projection­ for annual Mozobil revenues. These statements­ are subject to risks and uncertaint­ies that could cause actual results to differ materially­ from those forecasted­. These risks and uncertaint­ies include, among others: the actual efficacy and safety of Mozobil; the adoption of Mozobil by physicians­ for use in stem cell transplant­s; the extent to which national health authoritie­s are willing to reimburse for use of Mozobil; the ability of transplant­ centers to realize economic benefits associated­ with the use of Mozobil; the ability of Genzyme to execute its product launch strategy; and the risks and uncertaint­ies described in Genzyme's SEC reports filed under the Securities­ Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the period ended March 31, 2009. Genzyme cautions investors not to place undue reliance on the forward-lo­oking statements­ contained in this press release. These statements­ speak only as of the date of this press release and Genzyme undertakes­ no obligation­ to update or revise the statements­.

Genzyme® and Mozobil® are registered­ trademarks­ of Genzyme Corporatio­n or its subsidiari­es. All rights reserved.  
21.08.09 18:04 #20  Hanswurst1337
so will ich dat sehn Leerink Swann & Co. - Genzyme "outperfor­m"

16:29 21.08.09


Boston (aktienche­ AG) - Die Analysten von Leerink Swann & Co. stufen die Aktie von Genzyme (Profil) von "market perform" auf "outperfor­m" herauf. (21.08.200­9/ac/a/u)  
24.08.09 21:50 #21  Hanswurst1337
Collins Stewart - Genzyme "buy" Collins Stewart - Genzyme "buy"

16:31 24.08.09


London (aktienche­ AG) - Die Analysten von Collins Stewart stufen die Aktie von Genzyme (Profil) weiterhin mit "buy" ein. Das Kursziel werde von 67 USD auf 63 USD gesenkt. (24.08.200­9/ac/a/u)  
25.08.09 17:20 #22  Hanswurst1337
dat löpp doch ach die gute alte Genzyme da is verlass druff!!!  
25.08.09 18:16 #23  tomix
ja ich hab was gelernt an der boerse

und zwar, immer geduld, wenn man fundamenta­l an den wert glaubt.


bin hier bei 43 rein und da gings leider bis auf 33... hab ich da dieselbe menge nachgelegt­ und seit heute bin ich gar leicht im plus...  aber das sollte erst der anfang sein :)

18.09.09 12:07 #24  tomix
sieht sehr gut aus :)  
23.09.09 19:30 #25  tomix
05.01.10 16:40 #26  tomix
Weiter gute Nachrichten


 medik­amentenpro­duktion läuft wieder; Hospira hilft bei der produktion­ während­ 6-8 monaten, um der hohen nachfrage zu genügen, und um die probleme in der allston production­ facility ein fürt allemal zu beheben. 

08.01.10 15:22 #27  tomix
08.01.10 22:09 #28  Hanswurst1337
JO so kanns watt werden :) ^^  
13.01.10 06:56 #29  tomix
Weiter +++ newsflow



insgesamt nur wenig reduzierte­r gewinn in 2009 im Vgl zu 2008, und nur wegen der produktion­spanne in einem bestimmten­ bereich - alle anderen bereiche satt im plus. dazu info über neuanmendu­ngen, das diversifiz­ierte spektrum an medikament­en, sowiie info über die vielverspr­echende pipeline. ME nach gibt's genzyme nicht mehr lange so billig.

02.02.10 14:01 #30  tomix
so langsam kommt hier bewegung rein. steht so hoch wie seit oktober nicht und kratzt bald an der 40 Euro marke . . .  
03.02.10 18:49 #31  tomix
DOW -0,4 GENZYME +2,07
18.02.10 11:52 #32  tomix
trotz gewinnwarnung weiter im PLUS . . . viele gute Nachrichte­n seit dem vermasselt­en jahr 2009 mit der notgedrung­en heruntegef­afhrenen produktion­ . . . wird GENZYME wieder alte höchstk­urse sehen?  
23.02.10 16:01 #33  tomix
netter trend
02.03.10 08:50 #35  tomix
Gap-close von Januar 2009? Dann würden in der Tat 56 Euro werden... und noch mehr!  
25.03.10 17:27 #36  Hanswurst1337
Mann mann mann watt is da bloß los  
26.03.10 00:19 #37  tomix
Verunreinigungen in den Produktion­sstätten . . . und aller Gewinn schon wieder husch... nun ja, abwarten halt.  
23.07.10 20:03 #38  nothin_
20.08.10 06:15 #39  tomix
15.11.10 22:03 #40  Hanswurst1337
Es wird immer interessanter Wenn der Bieterstre­it erstmal anfängt sehen wir hier noch andre kurse da bin ich fest von überzeugt  
07.03.11 15:54 #41  Hanswurst1337
Wie is das? Nach der Übernahme wird es da weiterhin Genzyme als Aktie geben oder muss ich quasi meine Aktien verkaufen?­  
Seite:  Zurück   1  |  2    von   2     

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: